The leukocyte-shed short form of plasma soluble CD31 identifies coronary artery disease in patients at low risk: insights from the "Capire" study

Martino Deidda, Antonio Noto, Christian Cadeddu Dessalvi, Daniele Andreini, Felicita Andreotti, Ele Ferrannini, Roberto Latini, Aldo Maggioni, Marco Magnoni, Giuseppe Mercuro

Article2022

Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study

Federico Carbone, Jennifer Meessen, Marco Magnoni, Daniele Andreini, Aldo Maggioni, Roberto Latini, Fabrizio Montecucco

Article2019

IMPACT OF CORONARY ARTERY CALCIFICATION IN PATIENTS UNDERGOING REVASCULARIZATION FOR LEFT MAIN CORONARY ARTERY DISEASE: INSIGHTS FROM THE EXCEL TRIAL

Sabato Sorrentino, Roxana Mehran, Gennaro Giustino, Mengdan Liu, David E. Kandzari, Marie Claude Morice, Anthony Gershlick, Ovidiu Dressler, Joseph F. Sabik, A. Pieter Kappetein, Patrick W. Serruys, Gregg W. Stone

Journal of the American College of Cardiology

The leukocyte-shed short form of plasma soluble CD31 identifies coronary artery disease in patients at low risk: insights from the "Capire" study

Discussion(0)

Related publications

The leukocyte-shed short form of plasma soluble CD31 identifies coronary artery disease in patients at low risk: Insights from the “CAPIRE” study

Leukocyte-shed soluble CD31 unmasks coronary disease in low-risk outliers and provides source-specific inflammatory signatures of vulnerable plaques

Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study

Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study

IMPACT OF CORONARY ARTERY CALCIFICATION IN PATIENTS UNDERGOING REVASCULARIZATION FOR LEFT MAIN CORONARY ARTERY DISEASE: INSIGHTS FROM THE EXCEL TRIAL